MedDataX Logo

Intravenous Labetalol Versus Hydralazine in Preeclampsia

NCT ID: NCT06360601

Last Updated: 2024-12-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-04-01

Study Completion Date

2024-12-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We study the effect of intravenous labetalol versus hydralazine in sever preeclampsia patients on cerebral blood flow and neurological outcome

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Preeclampsia Severe

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Labetalol group

Group Type ACTIVE_COMPARATOR

Labetalol Injection

Intervention Type DRUG

Labetalol intravenous infusion 20ml/hr

Hydralazine group

Group Type ACTIVE_COMPARATOR

HydrALAZINE Injection

Intervention Type DRUG

Hydralazine intravenous infusion 5mg/hr

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Labetalol Injection

Labetalol intravenous infusion 20ml/hr

Intervention Type DRUG

HydrALAZINE Injection

Hydralazine intravenous infusion 5mg/hr

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patient with clinical diagnosis of sever preeclampsia

Exclusion Criteria

Patient with history of previous intracranial lesion Patient with history of heart disease/allergy to drug Patient with history of arrhythmia/anticoagulation Any craniotemporal lesion

\-
Minimum Eligible Age

25 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tanta University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mai Kamal

Lecturer of anaesthesia

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tanta Univeristy hospitals

Tanta, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

shimaa zahraa

Role: CONTACT

[email protected]
201550273707

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

aymen algamry

Role: primary

[email protected]
201008018208

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

36264PR589/3/24

Identifier Type: -

Identifier Source: org_study_id